RB

Roy Beck

Director Of Product Development at QT Imaging Holdings

Roy Beck currently serves as the Director of Product Development at QT Imaging Holdings since July 2025. Prior experience includes roles as Principal Electrical Engineer at Noah Medical and Senior Electrical Engineer at Vector Atomic, where contributions focused on advancing quantum technology. Previous positions also include Principal Engineer at QT Ultrasound LLC, Senior Electrical Engineer at Raydiance, Inc., and Senior Hardware Engineer at Cisco Systems. Roy Beck holds a Bachelor of Science in Electrical Engineering from San Francisco State University, earned between 1990 and 1992.

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


QT Imaging Holdings

The QTI team has been on an incredible journey, starting with a shared mission to create disruptive innovation to expand access to medical imaging while ensuring superior patient experience and improving health outcomes. We anchor our efforts in medical imaging because when the body can be scanned often and without harm, health conditions can be detected before symptoms appear. Chief among the new advancements in medical imaging is 3D body imaging. Today QTI focuses on our breast imaging technology, which is native 3D, high resolution, and generates reproducible image quality regardless of operator or breast size or tissue type. Current breast imaging paradigm leads to unnecessary concern and cost. ▪️Unlike mammography, QTI technology is effective in screening women with dense breasts, or 40% of women in US. ▪️35% of women aged 40-70 do not get screened. Of the 65% of women who get screened, 15% suffer unnecessary callbacks for ultrasounds, MRI, or biopsies. 80% of biopsies are benign. ▪️QTI’s technology can be a much-needed alternative for high risk women under 40, as cancers in younger women are usually aggressive and survival outcomes are poor. Our QT Imaging Breast Acoustic CT™ Scanner is the only true 3D imaging device, FDA cleared for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. There is no ionizing radiation or compression like in mammography or contrast dyes injections like in MRIs. The technology uniquely quantifies breast density. Surface-to-volume ratios and volumetric doubling time growth rate can be calculated to determine significance of lesions and improve specificity. This breast scanning system gives women the choice they deserve to ensure their breast health over time; for healthcare providers, a technology that is accessible, affordable, and accurately visualizes internal structures of the breast; and, for investors, a market segment extension and a purposeful investment opportunity.


Employees

11-50

Links